New Research Finds iCAD's ProFound AI Risk for Digital Breast Tomosynthesis is 2.4x More Accurate than Traditional Lifetime Risk ModelsGlobeNewsWire • 05/16/22
iCAD to Present at the Spring Into Action - Best Ideas Virtual Investor Conference on May 17th, 2022Accesswire • 05/12/22
iCAD, Inc. (ICAD) CEO Stacey Stevens on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/12/22
iCAD Showcases Innovative Breast Health Solutions Platform at National Consortium of Breast Centers (NCoBC) 31st Annual ConferenceGlobeNewsWire • 03/10/22
iCAD, Inc. (ICAD) CEO Michael Klein on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/01/22
iCAD Reports Financial Results for Fourth Quarter and Year Ended December 31, 2021GlobeNewsWire • 02/28/22
Analysts Estimate Icad (ICAD) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 02/21/22
iCAD to Report Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28GlobeNewsWire • 02/14/22
iCAD's Breast AI Platform Earns U.S. Department of Defense Authorization to OperateGlobeNewsWire • 01/24/22
iCAD to Participate at the 11th Annual LifeSci Partners Virtual Corporate Access EventGlobeNewsWire • 12/23/21
First Recurrent Glioblastoma Tumor is Treated with Xoft Brain IORT in the United StatesGlobeNewsWire • 12/14/21
iCAD, Inc. (ICAD) CEO Michael Klein on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/10/21
iCAD Unveils Next Generation Technologies at Journées Francophones de Radiologie (October 8-11, Paris, France)GlobeNewsWire • 10/07/21